GeneDx Holdings Corp. (WGS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

GeneDx Holdings Corp. (WGS) Healthcare & Pipeline Overview

GeneDx Holdings Corp. leverages AI and machine learning through its Centrellis platform to analyze clinical and genomic data, aiming to transform healthcare by creating dynamic models of human health. As a patient-centered health intelligence company, GeneDx provides science-driven solutions to address critical medical needs within the healthcare information services sector.

What Is the Investment Thesis for WGS?

GeneDx Holdings Corp. presents an investment opportunity centered on its innovative Centrellis platform and its application of AI and machine learning in healthcare. With a market capitalization of $2.50B, the company operates in the high-growth healthcare information services sector. Key value drivers include the expansion of its Centrellis platform and increasing adoption by healthcare providers. Upcoming catalysts include potential partnerships with pharmaceutical companies and further development of its AI-driven diagnostic tools. However, the company's negative profit margin of -17.6% and a high beta of 2.19 indicate significant risk, requiring careful consideration of market volatility and financial performance.

Based on FMP financials and quantitative analysis

WGS Key Highlights

Market capitalization of $2.50B, reflecting investor confidence in the company's growth potential.

• Gross margin of 68.3%, indicating strong pricing power and efficient service delivery.
• Negative profit margin of -17.6%, highlighting the need for improved cost management and revenue generation.
• Beta of 2.19, indicating high volatility compared to the broader market.
• No dividend yield, suggesting that the company is reinvesting earnings for growth.

Who Are WGS's Competitors?

WGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are WGS's Key Strengths?

Innovative Centrellis platform leveraging AI and machine learning.

• Strong focus on personalized medicine and data-driven healthcare.
• Experienced leadership team with expertise in healthcare and technology.
• Growing database of clinical and genomic data.

What Are WGS's Weaknesses?

Negative profit margin indicating financial challenges.

• High beta suggesting significant market volatility.
• Reliance on partnerships for revenue generation.
• Limited geographic presence.

What Could Drive WGS Stock Higher?

Potential partnerships with pharmaceutical companies to leverage Centrellis for drug discovery and development.

• Development and launch of new AI-driven diagnostic tools.
• Expansion of the Centrellis platform to include additional data sources and functionalities.
• Increasing adoption of Centrellis by healthcare providers and researchers.
• Growing focus on personalized medicine driving demand for AI-driven solutions.

What Are the Key Risks for WGS?

Negative return on equity (-38.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 41.40 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Intense competition in the healthcare information services sector.
• Regulatory changes impacting data privacy and security.
• Economic downturn affecting healthcare spending.
• Negative profit margin indicating financial challenges.
• High beta suggesting significant market volatility.

What Are the Growth Opportunities for WGS?

• Expansion of Centrellis Platform: GeneDx has a significant opportunity to expand the capabilities and reach of its Centrellis health intelligence platform. By integrating additional data sources and developing new AI-driven applications, Centrellis can become an indispensable tool for healthcare providers and researchers. The market for AI in healthcare is projected to reach $45.2 billion by 2026, offering a substantial growth runway for GeneDx.
• Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to leverage Centrellis for drug discovery and development represents a major growth opportunity. By providing AI-driven insights into disease mechanisms and patient responses, GeneDx can accelerate the development of new therapies and improve clinical trial outcomes. This strategic direction aligns with the industry's increasing focus on precision medicine and personalized treatments.
• Development of AI-Driven Diagnostic Tools: GeneDx can further capitalize on its AI capabilities by developing diagnostic tools that enable earlier and more accurate detection of diseases. These tools can be integrated into clinical workflows to improve patient outcomes and reduce healthcare costs.
• Geographic Expansion: Expanding its operations beyond its current geographic footprint represents another key growth opportunity for GeneDx. By targeting new markets and establishing partnerships with local healthcare providers, GeneDx can increase its customer base and revenue streams.
• Personalized Medicine Initiatives: The increasing focus on personalized medicine creates a favorable environment for GeneDx's AI-driven approach. By leveraging its Centrellis platform to tailor treatments to individual patients, GeneDx can improve outcomes and reduce healthcare costs. The personalized medicine market is expected to reach $2.4 trillion by 2028, providing a substantial growth opportunity for GeneDx.

What Are WGS's Competitive Advantages?

• Proprietary Centrellis health intelligence platform.
• Expertise in applying AI and machine learning to healthcare data.
• Strong relationships with healthcare providers and pharmaceutical companies.
• Large and growing database of clinical and genomic data.

What Does WGS Do?

Founded in October 2015 by Eric Schadt and headquartered in Stamford, CT, GeneDx Holdings Corp. operates as a patient-centered health intelligence company. The company is dedicated to transforming healthcare by applying advanced artificial intelligence (AI) and machine learning techniques to vast, multidimensional, and longitudinal clinical and genomic data sets. This approach enables GeneDx to construct dynamic models of human health, ultimately defining optimal and individualized health trajectories for patients. At the core of GeneDx's operations is its Centrellis health intelligence platform. This platform is designed to generate a more comprehensive and nuanced understanding of both disease and wellness. By synthesizing complex data, Centrellis provides science-driven solutions targeted at addressing some of the most pressing medical challenges. GeneDx's focus on leveraging data-driven insights positions it as a key player in the evolving landscape of healthcare information services, aiming to improve patient outcomes and healthcare delivery through innovative technology.

What Products and Services Does WGS Offer?

• Applies AI and machine learning to clinical and genomic data.
• Develops dynamic models of human health.
• Defines individualized health trajectories.
• Offers the Centrellis health intelligence platform.
• Provides science-driven solutions for medical needs.
• Transforms healthcare through data-driven insights.

How Does WGS Make Money?

• Generates revenue through subscriptions to the Centrellis platform.
• Partners with pharmaceutical companies for drug discovery and development.
• Offers AI-driven diagnostic tools to healthcare providers.
• Provides personalized medicine solutions based on genomic data.

What Industry Does WGS Operate In?

GeneDx Holdings Corp. operates within the rapidly expanding healthcare information services sector. This industry is characterized by the increasing adoption of AI and machine learning technologies to improve healthcare outcomes and reduce costs. The competitive landscape includes companies like Immunovant, Inc. (IMVT) and Oscar Health, Inc. (OSCR), each focusing on different aspects of healthcare innovation. GeneDx's unique approach of applying AI to multidimensional clinical and genomic data positions it to capitalize on the growing demand for personalized and data-driven healthcare solutions.

Who Are WGS's Key Customers?

• Healthcare providers seeking to improve patient outcomes.
• Pharmaceutical companies engaged in drug discovery and development.
• Researchers studying disease mechanisms and personalized medicine.
• Patients seeking personalized treatment plans.

GeneDx Holdings Corp. (WGS) Valuation Context

Valued at $2.50B, WGS is classified as a mid-cap stock. Analyst price targets span from $63.00 to $90.00, with a consensus of $79.50. At the current price of $83.96, that implies roughly 5% downside from the consensus target. Relative to its peer group, WGS's quantitative score of 32/100 is below the peer average of 65/100.

WGS Revenue & Earnings Trend

In Q2 FY2026, WGS generated $114.4M in top-line revenue, marking a sequential increase of 11.9%. The company recorded a net loss of $17.7M, with diluted EPS of $-0.60. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, WGS averaged $-0.92 in diluted EPS.

Company Profile

GeneDx Holdings Corp. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Katherine A. Stueland. WGS has traded publicly since 2020.

Return on equity for GeneDx Holdings Corp. stands at -38.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.

GeneDx Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.77 places it in the grey zone, a middle ground that warrants monitoring.

GeneDx Holdings Corp. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 270.8% above estimates on average.

Over the past six months, GeneDx Holdings Corp. insiders filed 15 SEC Form 4 transactions — 6 sales and 9 purchases. On net that is roughly 48K shares acquired (about $31K) — insiders putting money in tends to read as conviction.

WGS Financials

WGS Latest News

WGS Analyst Consensus

WGS MoonshotScore

Latest GeneDx Holdings Corp. Analysis

GeneDx Holdings Corp. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources